white → yellow2
dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.
Methylphenidate
Methylphenidate
Ritalin, Concerta, Methylin, Vitamin R, R-ball
Methylphenidate is a central nervous system stimulant1 of the phenidate class. First synthesized in 1944,citation needed it became one of the most widely prescribed medications for attention deficit hyperactivity disorder (ADHD) and narcolepsy, marketed under brands such as Ritalin1 and Concerta2. Outside clinical settings, it is used recreationally3 and as a cognitive enhancer,3 though its stimulant and euphoric effects are generally considered less pronounced than those of amphetamines.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Threshold~5 mg
Light5-15 mg
Moderate15-35 mg
Strong35-60 mg
Heavy60+ mg
Bioavailability
11-52%
Duration
Onset30-60 minutes
Come Up20-45 minutes
Peak60-90 minutes
Offset45-60 minutes
After Effects2-6 hours
Total3-4 hours
Half-life
2-3 hours
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
Effects vary widely by individual, dose, and context.
Physical
The physical effects of methylphenidate can be broken down into several components which progressively intensify proportional to dosage.
Cognitive
The cognitive effects of methylphenidate can be broken down into several components which progressively intensify proportional to dosage. The general head space of methylphenidate is described by many as one of extreme mental stimulation, increased focus, and powerful euphoria. It contains a large number of typical stimulant cognitive effects. Although negative side effects are usually mild at low to moderate dosages, they become increasingly likely to manifest themselves with higher amounts or extended usage. This particularly holds true during the offset of the experience.
Pharmacology
Pharmacodynamics
Methylphenidate acts primarily as a norepinephrine-dopamine reuptake inhibitor (NDRI)4, blocking both the dopamine transporter (DAT) and the norepinephrine transporter (NET) to increase extraneuronal concentrations of these neurotransmitters.citation needed Its activity is most pronounced at the dopamine transporter, with a lesser degree of norepinephrine reuptake inhibition. Both enantiomers of the racemic mixture display affinity for the serotonin 5-HT1A receptor, though no direct binding to the serotonin transporter has been observed.5 Initial findings also suggested affinity at the 5-HT2B receptor, but a subsequent study found no significant activity at this site.citation needed
Pharmacokinetics
Methylphenidate undergoes extensive first-pass metabolism in the liver, resulting in oral bioavailability of approximately 11 to 52% with considerable individual variation.citation needed It is rapidly metabolized by the carboxylesterase enzyme CES1A1 via de-esterification to ritalinic acid, which possesses little to no pharmacological activity. The d-isomer is substantially more bioavailable than the l-isomer when taken orally and is primarily responsible for the pharmacological effects of the racemic mixture. Approximately 97% of the metabolized drug is excreted in urine, with less than 1% appearing unchanged. The elimination half-life of immediate-release formulations is approximately 2 to 3 hours.
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
AcebutololAceclofenacAcemetacinAcenocoumarolAcetazolamide
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Full Tolerance
Tolerance develops relatively quickly with repeated use, particularly to the euphoric and reinforcing effects. With continued high-dose or abusive use, progressively higher doses may be required to achieve the same effects.
Cross Tolerance
Other dopaminergic stimulants
Harm Potential
Addiction & Dependence
Psychological
ModerateMethylphenidate has moderate liability among addictive drugs, with addiction and psychological dependence occurring primarily when used at high doses or in non-medical contexts. At therapeutic doses, it does not sufficiently activate the reward system to cause addiction; however, its dopamine reuptake inhibition can induce euphoria at higher doses, contributing to abuse potential.citation needed
Physical
LowPhysical dependence and withdrawal are mainly reported with high-dose or non-medical use and are uncommon at therapeutic doses.citation needed Withdrawal symptoms following abrupt discontinuation may include lethargy, apathy, depression, and paranoia, but these are not life-threatening.
Toxicity
Cardiovascular
Acute cardiovascular effects including elevated heart rate, blood pressure changes, and palpitations occur during use; these are typically mild at therapeutic doses.citation needed FDA studies found no association between medical use and serious cardiovascular events such as sudden death, heart attack, or stroke. Higher doses and overdose may cause cardiac arrhythmias.
Hepatic
Liver toxicity from methylphenidate is extremely rare; limited evidence suggests the risk may increase when combined with β-adrenergic agonists.citation needed
Musculoskeletal
Rhabdomyolysis has been reported primarily in severe overdose situations or with large doses that induce hyperthermia and excessive muscular activity.citation needed
Vascular
Intravenous injection of crushed tablet preparations can cause severe toxic reactions including abscess formation, tissue necrosis, and pulmonary or cerebral embolism due to insoluble binders and fillers.citation needed
Growth and Development
Long-term treatment in children has been associated with mild reductions in height, estimated at approximately 1 cm or less per year during the first three years, with a total decrease of about 3 cm over 10 years of continuous treatment.citation needed
Psychosis Risk
Methylphenidate can worsen psychosis in people who are already psychotic; in very rare cases, it has been associated with the emergence of new psychotic symptoms.citation needed Visual hallucinations are very rarely reported. Overdose may trigger hallucinations and delirium. Should be used with extreme caution in people with bipolar disorder due to potential induction of mania or hypomania.
Seizure Risk
Seizures and convulsions are associated with abusive use, higher doses, and severe overdose rather than typical therapeutic use.citation needed Convulsions in overdose may be followed by coma.
History & Culture
Discovery and Synthesis
Methylphenidate was first synthesized in 1944 by Swiss chemist Leandro Panizzon while working for the pharmaceutical company CIBA (now Novartis).citation needed Panizzon named the compound after his wife Marguerite, nicknamed "Rita," who became the first person to take the…
Legality
By Country
Illegal1
RussiaIllegalGovernment Resolution No. 681 of 30 June 1998, List I20
Methylphenidate is included in Russia's List I of narcotic drugs and psychotropic substances whose circulation is prohibited. The List I classification does not provide for ordinary medical prescription supply.
Prescription16
United StatesControlled prescription medicationAvailable as a prescription medication with a blackbox warning indicating high potential for abuse and dependence.34 Multiple brand name formulations (including Adhansia XR, Metadate ER, Methylin)3 and generic products are marketed for medical use.34
By state
Across the 50 states, D.C., and the permanent territories, most jurisdictions treat methylphenidate consistently with federal law, though a number of states impose their own controls or classifications that diverge from the federal position.
United States Virgin IslandsPrescription only
ChilePrescription onlySupreme Decree No. 405/1983, Regulation of Psychotropic Products10
Methylphenidate is listed in Chile's psychotropic-products regulation. Its import, manufacture, dispensing, possession, and use are regulated, with medical supply subject to prescription controls.
GermanyPrescription onlyBetäubungsmittelgesetz, Anlage III14
Methylphenidate is listed in Anlage III of Germany's Narcotics Act. Anlage III substances are marketable and prescribable narcotics subject to the BtM prescription system.
IndiaPrescription onlyDrugs and Cosmetics Rules 1945, Schedule X15
Methylphenidate is listed in Schedule X to India's Drugs and Cosmetics Rules. Retail supply requires a prescription and the additional recordkeeping and retention controls for Schedule X medicines.
IrelandPrescription onlyMisuse of Drugs Regulations 2017, Schedule 216
Methylphenidate is listed in Schedule 2 to Ireland's Misuse of Drugs Regulations. Supply is subject to the controlled-drug prescription regime.
JapanPrescription only
New ZealandPrescription onlyMisuse of Drugs Act 1975, Schedule 219
Methylphenidate is a Class B controlled drug in New Zealand. It may be supplied for treatment only within the controlled-drug prescription requirements.
SingaporePrescription onlyMisuse of Drugs Act 1973, First Schedule21
Methylphenidate is a Class C controlled drug under Singapore's Misuse of Drugs Act. Authorized medical supply is regulated through controlled-drug prescription and possession rules.
South AfricaPrescription onlyMedicines and Related Substances Act 101 of 1965, Schedule 622
Methylphenidate is a Schedule 6 medicine in South Africa. It is therefore available only on prescription and under the enhanced controls that apply to Schedule 6 medicines.
SwedenPrescription onlyLVFS 2011:10, list of narcotic drugs23
Methylphenidate is listed in Sweden's narcotic-drug schedule II. It may be used medically but is subject to controlled prescription and handling rules.
SwitzerlandPrescription onlyBetäubungsmittelverzeichnisverordnung-EDI, Verzeichnis a24
Methylphenidate is listed in Swiss Schedule a for controlled substances. It is available for medical treatment under narcotics-control and prescription requirements.
United Arab EmiratesPrescription onlyFederal Decree-Law No. 30 of 2021 on Combating Narcotic Drugs and Psychotropic Substances, Schedule 62728
Methylphenidate is listed as a Schedule II psychotropic substance in the United Arab Emirates. Pharmacy dispensing requires a valid medical prescription, and travelers require the specified medical documentation.
United KingdomPrescription onlyMisuse of Drugs Act 1971; Misuse of Drugs Regulations 2001; Misuse of Drugs Regulations (Northern Ireland) 20022930313233
Methylphenidate is a Class B controlled drug under the Misuse of Drugs Act 1971. It is in Schedule 2 to the Misuse of Drugs Regulations 2001 in England, Wales and Scotland, and to the Misuse of Drugs Regulations (Northern Ireland) 2002 in Northern Ireland. Unauthorised possession, production, supply, importation and exportation are offences; authorised medical supplies are subject to controlled-drug prescription and record-keeping requirements, and methylphenidate is only available on prescription. The two regional Schedule 2 regulations came into force on 1 February 2002.
References
Source Pages
Citations
- RITALIN- methylphenidate hydrochloride tablet. DailyMed (n.d.). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0bf0835-6a2f-4067-a158-8b86c4b0668a12
- CONCERTA- methylphenidate hydrochloride tablet, extended release. DailyMed (n.d.). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a88218c-5b18-4220-8f56-526de1a276cd1
- Methylphenidate - StatPearls. NCBI Bookshelf / StatPearls (n.d.). https://www.ncbi.nlm.nih.gov/books/NBK482451/123
- Javier Quintero, José R. Gutiérrez-Casares, & Cecilio Álamo. (2022). Molecular Characterisation of the Mechanism of Action of Stimulant Drugs Lisdexamfetamine and Methylphenidate on ADHD Neurobiology: A Review. Neurology and Therapy. https://doi.org/10.1007/s40120-022-00392-21
- John S. Markowitz, C. Lindsay DeVane, Linda K. Pestreich, Kennerly S. Patrick, & Rafael Muniz. (December 2006). A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study. Journal of Child and Adolescent Psychopharmacology, 16(6), 687–698. https://doi.org/10.1089/cap.2006.16.68712
- Markowitz JS, DeVane CL, Ramamoorthy S, & Zhu HJ. (February 2009). The psychostimulant d-threo-(R,R)-methylphenidate binds as an agonist to the 5HT(1A) receptor. Die Pharmazie, 64(2), 123–125. https://pubmed.ncbi.nlm.nih.gov/19322953/1
- Methylphenidate Drug Usage Statistics, United States, 2014 - 2023. ClinCalc (n.d.). https://clincalc.com/DrugStats/Drugs/Methylphenidate1
- Portaria SVS/MS No. 344/1998, List A3. antigo.anvisa.gov.br (n.d.). https://antigo.anvisa.gov.br/documents/10181/2718376/PRT_SVS_344_1998_COMP.pdf1
- Portaria SVS/MS No. 344/1998, List A3. gov.br (n.d.). https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/controlados/lista-substancias1
- Supreme Decree No. 405/1983, Regulation of Psychotropic Products. bcn.cl (n.d.). https://www.bcn.cl/leychile/Navegar?idNorma=130661
Further Reading
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass review
A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes7 human edits · latest
Times are UTCNewest first
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the Methylphenidate article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.